HD12 for Advanced Stages

University of Cologne

Overview

This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Hodgkin´s Lymphoma

Interventions

CyclophosphamideDRUG

AdriamycinDRUG

EtoposideDRUG

ProcarbazineDRUG

Eligibility

Sex: ALLMin age: 16 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hodgkin´s lymphoma (histologically proven) * CS(PS) IIB with one or both of the risk factors: 1. bulky mediastinal mass (\> 1/3 of maximum transverse thorax diameter) 2. extranodal involvement * CS(PS) III, IV * written informaed consent Exclusion Criteria: * Leukocytes \<3000/microl * Platelets \<100000/microl * Hodgkin´s Disease as "composite lymphoma" * Activity index (WHO) \< grade 2

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.